In research and development, we invested more than $17 billion or 19.4% of sales. We remain one of the top investors in R&D across all industries. 2024 marked the 62nd consecutive year of dividend increases. We know this use of capital is a priority for our investors, and we plan to c...
Texas Instruments and Other Overlooked Dividend Aristocrat Stocks Nov. 5, 2024 10:33 a.m. ET AI Robot Trader Dumped Microsoft, Amazon Stocks and Went Defensive. Here’s What It Bought. Oct. 28, 2024 9:28 a.m. ET What the Election Will Mean for CVS, Pfizer, and Other Healthcare Stock...
>60 Consecutive years of dividend increases >60% 5-Year free cash flow returned to shareholders >65% Of sales come from #1 or #2 global market share position2023 Investor fact sheet Investor news Loading ... See all investor news Events and presentations April 15, 2025 Johnson & Johnson...
The strength of our diversified business enables us to more than offset volatility in one part of our business but yet be in a position to once again increase 2024 guidance for the enterprise. Before diving into the results, I'll take a moment to touch on some enterprisewide updates from t...
trailing 12 month 4.91 dividend rate, indicated annual 4.96 price volume beta 0.49 volume - avg. trading volume for the last 3 months 178.90 volume - avg. trading volume for the last ten days 8.40 management effectiveness return on average assets - most recent quarter (annualized) 7.68 return ...
Jun 5, 2024 1:30 PM EDT These stocks could start paying dividends soon The S&P 500 dividend yield stands at 1.34%. ABNBAZOPYPL Stock Investing News, Analysis and Tips May 23, 2024 4:28 PM EDT Stock Market Today: Nvidia soars, stocks edge lower on inflation risks Stocks are set for ...
dividend legend at a discount dt invest thu, dec. 19, 2024 29 comments johnson & johnson is a better dividend stock than amgen in our view envision research fri, dec. 06, 2024 30 comments see all analysis » jn...
the use of cash and in a tax-free manner. We maintained our current quarterly dividend per share, and we’ve retained approximately 180 million shares of Kenvue’s stock that provides cash proceeds for future flexibility. We will see the full impact to EPS of the share reduction in 2024....
Dividend Roundup: Why I Prefer Johnson & Johnson Over PfizerEnvision ResearchWed, Jan. 0821 Comments Johnson & Johnson: A Potential Beneficiary Of A Great RotationMacroGirlTue, Jan. 072 Comments Share your Analysis on JNJ:CASubmit an article now See All Analysis » JNJ:CA News Short bets ag...
DividendsDividend Stocks Have Slumped. Why UPS and Others May Bounce Back. Jan. 21, 2025 at 2:09 p.m. ETby Barron's Johnson & Johnson Gets FDA OK For Spravato as Monotherapy Jan. 21, 2025 at 8:42 a.m. ET J&J Initiates Bid for FDA Approval of TAR-200 in Bladder Cancer ...